VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,403,651 | -0.5% | 380,613 | -2.5% | 0.23% | -1.7% |
| Q2 2023 | $19,499,373 | +108.1% | 390,456 | +56.2% | 0.23% | +81.9% |
| Q1 2023 | $9,370,000 | -21.8% | 250,000 | 0.0% | 0.13% | -20.6% |
| Q4 2022 | $11,987,500 | +154.3% | 250,000 | +27.3% | 0.16% | +142.4% |
| Q3 2022 | $4,714,000 | -53.5% | 196,429 | -57.9% | 0.07% | -57.7% |
| Q2 2022 | $10,147,000 | +337.9% | 466,324 | +378.8% | 0.16% | +372.7% |
| Q4 2021 | $2,317,000 | +218.3% | 97,396 | +323.0% | 0.03% | +13.8% |
| Q2 2020 | $728,000 | – | 23,026 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |